Table 2.
Distribution of patients in relation to the target ranges of piperacillin
| Patient groups, number of patientsa | Percentages of patients who attain the targets | |||
|---|---|---|---|---|
| trough values ≥ 22.5 mg/L | ≥50 % of time > 90 mg/L | |||
| Day 1 | Day 4 | Day 1 | Day 4 | |
| Total patients, n = 60 | 53 % | 52 % | 40 % | 38 % |
| With lowest quartileb of CrCl, n = 11 | 100 % | 86 % | 62 % | 67 % |
| With highest quartilec of CrCl, n = 11 | 0 % | 0 % | 9 % | 0 % |
| With RRT, n = 10 | 80 % | 71 % | 62 % | 57 % |
| Without RRT, n = 50 | 48 % | 49 % | 36 % | 33 % |
| Receiving 2 × 4.5 g PIP/TAZ daily, n = 15d | 100 % | 82 % | 64 % | 50 % |
| Receiving 3 × 4.5 g PIP/TAZ daily, n = 45e | 38 % | 35 % | 33 % | 32 % |
CrCl creatinine clearance, RRT renal replacement therapy, PIP/TAZ piperacillin-tazobactam
aNumbers as determined on day 1 are presented
bCreatinine clearance 2–19 mL/min
cCreatinine clearance 108–233 mL/min
dComprising on first study day three patients with RRT and 12 patients without RRT. The latter patients presented a median creatinine clearance of 11 mL/min (interquartile range: 6–19 mL/min)
eComprising on first study day seven patients with RRT and 38 patients without RRT. The latter patients presented a median creatinine clearance of 70 mL/min (interquartile range: 40–130 mL/min)